Of interest, in preclinical models of CF, the ALX/FPR2 agonists LXA4, AnxA1, RvD1, and 15-epi-LXA4 proved beneficial in dampening neutrophil infiltration, reducing the release of pro-inflammatory mediators by CF cells, and limiting collateral tissue damage, demonstrating their therapeutic potential for treating chronic lung inflammation21,23–25. The gene discussed is ANXA1; the disease is cystic fibrosis.